RxDoctor Payments Data

Ashwin Jathavedam, MD

Internal Medicine · Englewood, NJNPI 1609862747

Payments from drug & device makers

$2,432in general payments, 2019–2025

Across 151 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$571
  • Merck$329
  • Viiv Healthcare Company$320
  • Insmed, Inc.$289
  • AbbVie$193
  • Johnson & Johnson$138
  • plus $593 from 21 others

What the payments were for

  • Food & beverage$2,33396%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,432 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$269,926
Medicare patients
848
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala137$599,534
TriumeqAbacavir/Dolutegravir/Lamivudi125$525,143
IsentressRaltegravir Potassium44$90,445
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$88,370
TivicayDolutegravir Sodium28$71,270
DescovyEmtricitabine/Tenofov Alafenam15$45,339
JulucaDolutegravir/Rilpivirine11$44,720
PrezcobixDarunavir/Cobicistat14$38,758
PercocetOxycodone Hcl/Acetaminophen19$32,389
JanuviaSitagliptin Phosphate18$24,190
EliquisApixaban17$23,603
JardianceEmpagliflozin15$18,766
Maraviroc12$16,651
OxycontinOxycodone Hcl20$15,920
Etravirine12$13,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$571$644,873152 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca$320$641,133164 claims
MerckIsentress, Januvia$329$114,63462 claims
Johnson & JohnsonPrezcobix$138$38,75814 claims
PfizerEliquis$15$23,60317 claims
GSKTrelegy Ellipta$81$6,96012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →